JAK3 Inhibitor is robust in inhibiting NKTL while EZH2 inhibitors are not efficacious. (A) Immunoblot analysis of NKYS cells treated with EZH2 inhibitor GSK126 (GSK) at indicated concentration for 3 days and 4 days. (B) Cell viability of NKYS cells treated with GSK. (C) Cell viability of NKYS cells treated with PF and GSK combination. No obvious synergistic effect. (D) Immunoblot analysis of NKTL cells treated with EZH2 inhibitor EPZ. (E-F) Cell viability assay of NKTL cells treated with EPZ as a single agent or combination with PF. (E) for NKYS and (F) for KHYG. (G) Immunoblot analysis of KHYG cells treated with EZH2 inhibitor SAH-EZH2. Cells were treated with SAH-EZH2 twice daily. (H) Cell cycle analysis of NKYS cells treated with PF for 24 hours. (I) Cell viability assay of PF-treated NKYS cells ectopically expressing EZH2 WT/Y244A/Y244D. Data are presented as mean values ± SD of triplicates. *P < .05 (Student t test). DMSO, dimethyl sulfoxide.